Incretin Atlas › Trials › Amycretin oral phase 1
Amycretin oral phase 1
Amycretin · obesity
Design
- Molecule(s)
- Amycretin
- Population
- obesity
- Phase
- 1
- Participants
- 144
- Duration
- 12 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| oral amycretin 50 mg | obesity | 12 | 144 | — | —−10.4 % vs −1.2 % estimand not specified | −0.2 vs +0.0 | — | — | 31.0 vs 8.0 | 38.0 vs 0.0 | 0.0 vs 0.0 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- oral amycretin 50 mg: Part C1, 50 mg once daily (n=16 vs 12 placebo); observed mean change, estimand not stated.
Verbatim quotes from the source (5)
- oral amycretin 50 mg · nausea · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
Nausea 5 (31%) 6 12 (75%) 14 15 (94%) 18 1 (8%)
- oral amycretin 50 mg · sae · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
Serious adverse event Yes 0 0 0 0 1 (6%) 1 0 0
- oral amycretin 50 mg · vomiting · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
Vomiting 6 (38%) 7 9 (56%) 11 10 (63%) 11 0 0
- oral amycretin 50 mg · hba1c · Table 3
HbA1c, % Screening, mean (SD) 5·2 (0·4) 5·2 (0·3) 5·4 (0·4) 5·3 (0·4) Day 85, mean (SD) 5·0 (0·3) 5·0 (0·2) 5·1 (0·2) 5·3 (0·3) Change from day 1 to day 85, mean (SD) –0·2 (0·2) –0·3 (0·3) –0·3 (0·2) 0·0 (0·2) ETD (95% C
- oral amycretin 50 mg · weight_unsp · Table 3 (exploratory PD endpoints part C/D), column 1 = Amyc
Amycretin 50 mg (n=16) Amycretin 2 × 50 mg (n=16) Amycretin 2 × 25 mg (n=16) Placebo* (n=12) Bodyweight, % Change from day 1 to day 85, mean (SD) –10·4 (4·6) –13·1 (4·8) –12·2 (4·5) –1·2 (2·4) Minimum change –2·2 –6·2 –4
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Amycretin oral phase 1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-oral-phase-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.